Exploring Insmed's Key Growth Drivers...
Russell Rotation: YTD Market Capitalizations Swelling for Small-caps
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 4.66% on an annualized basis producing an average annual return of 15.55%. Currently, Insmed has a market capitalization of $
Unusual Options Activity: ENTG, INSM and Others Attract Market Bets, ENTG V/OI Ratio Reaches 357.1
EST Jul 16th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Looking Into Insmed's Recent Short Interest
Insmed's (NYSE:INSM) short percent of float has risen 10.99% since its last report. The company recently reported that it has 12.83 million shares sold short, which is 7.98% of all regular shares
What Makes Insmed Incorporated (INSM) a Prospective Investment?
$1000 Invested In This Stock 10 Years Ago Would Be Worth $4,300 Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 4.84% on an annualized basis producing an average annual return of 15.98%. Currently, Insmed has a market capitalization of $
Insmed Is Maintained at Overweight by Morgan Stanley
Insmed Is Maintained at Overweight by Morgan
Morgan Stanley Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $85
Morgan Stanley analyst Jeffrey Hung maintains $Insmed(INSM.US)$ with a buy rating, and adjusts the target price from $60 to $85.According to TipRanks data, the analyst has a success rate of 57.6%
Barclays Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Barclays analyst Leon Wang maintains $Insmed(INSM.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 76.9% and a total
Barclays Keeps Their Buy Rating on Insmed (INSM)
Unusual Options Activity: GOOG, BKR and Others Attract Market Bets, GOOG V/OI Ratio Reaches 357.1
EST Jul 11th Afternoon Delivery - In the last two hours of trading, 8 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Goldman Sachs Raises Price Target on Insmed to $102 From $74, Maintains Buy Rating
Insmed (INSM) has an average rating of buy and price targets ranging from $60 to $102, according to analysts by Capital IQ.Price: 71.24, Change: +0.97, Percent Change: +1.38
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $102
Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $74 to $102.
Insmed's (NASDAQ:INSM) Potential Groundbreaking Drug
Insmed (NASDAQ:INSM) is making waves in the market with successful results from a Phase 3 trial of potentially a groundbreaking drug in Brensocatib for non-cystic fibrosis bronchiectasis patients. The drug could pioneer a new treatment era for this difficult-to-treat patient population by achieving its primary objective of significant reductions in the annual rate of pulmonary exacerbations, as well as several secondary endpoints.
Insmed Price Target Raised to $95.00/Share From $70.00 by Guggenheim
Insmed Price Target Raised to $95.00/Share From $70.00 by
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $95
Guggenheim analyst Vamil Divan maintains $Insmed(INSM.US)$ with a buy rating, and adjusts the target price from $54 to $95.According to TipRanks data, the analyst has a success rate of 53.7% and a
Express News | Insmed Inc : Guggenheim Raises Target Price to $95 From $70
HC Wainwright Adjusts Price Target on Insmed to $90 From $70, Maintains Buy Rating
Insmed (INSM) has an average rating of buy and price targets ranging from $60 to $90, according to analysts by Capital IQ.
American Express To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.B. Riley Se